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Preface
Understanding the nature and scale of the drugs problem is critical for effective policymaking and 
action. As such, the EMCDDA uses a variety of monitoring methods and tools that offer countries 
a ‘common language’ with which to interpret the drugs phenomenon. Among these instruments are 
the five key epidemiological indicators, one of which is the Treatment demand indicator (TDI).
The purpose of the TDI, which was established in 2000 following the work of the Council of 
Europe cooperation group to combat drug use and illicit trafficking (the Pompidou Group), is 
to gather comparable and reliable information on the number and characteristics of drug users 
presenting for treatment in EU Member States. It provides a measure of treatment demand, 
indicates trends in the extent of problem drug use and provides profiles of problem drug users, 
while also identifying patterns in the use and uptake of treatment facilities.
This manual presents a revised edition of the TDI protocol (version 2.0). After 10 years of data 
collection at the European level using this protocol, modification is now required so the TDI can 
better reflect the changes that have occurred over this period not only in the situation of drug use, 
but also in the treatment system and national and international information systems.
The revised protocol (version 3.0) represents a significant step forward for the indicator, and has 
been made possible thanks to the coordinated effort and commitment, for over 2 years, of the 
national TDI experts and national focal points together with the EMCDDA. 
Wolfgang Götz
Director, EMCDDA


1C
H
A
PTER 
O
N
E
C
H
A
PTER 
O
N
E
15
1
Chapter 1
Introduction 
History 
The history of the Treatment demand indicator (TDI) can be traced back to almost 20 years ago, 
when a first harmonised data collection form was defined. The aim of the protocol was to provide 
professionals and researchers with a common European methodology for collecting and reporting 
core data on the profile of drug users in contact with treatment services.
The core data set was built on the national experiences of data collection in the drug treatment 
system, often already existing before the establishment of the TDI. In the countries where a national 
data collection system did not exist, the TDI was frequently adopted as a minimum data set for a more 
extended national monitoring system of drug users in treatment (European Addiction Research, 1999).
The first actor who defined a common protocol for collecting data on people entering drug 
treatment was the Pompidou Group (PG), who coordinated studies at city level (in Dublin and 
London in 1991) and a developmental project in 11 cities and the creation of a European expert 
group which met several times to discuss and agree the methodological guidelines. The PG 
protocol was published in 1994 (Hartnoll, 1994; Stauffacher and Kokkevi, 1999) and was first 
implemented at city level and then at country level in west European countries; in a second phase, 
it was implemented in central and east European countries. 
In 1994, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was 
established, and it assumed responsibility for collecting European treatment demand data.
The EMCDDA/Pompidou Group Treatment demand indicator 2.0 (Simon et al., 2000) was 
published based on a revision of the first Pompidou Group protocol. It was preceded by 
a feasibility assessment concerning methodology and data collection (Origer, 1996) and by an 
evaluation of national experiences of data reporting using the TDI (Simon and Pfeiffer, 1999).
Since 2000, the EMCDDA has been implementing the data reporting from the EU Member States 
and adopted formal agreements with the Member Sates to stimulate and facilitate data collection 
and reporting from national to European level.
The five EMCDDA key epidemiological indicators, including the TDI, were formally adopted by the 
EMCDDA Management Board (EMCDDA Managment Board, 2001) and by the Council of the 
16
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European Union in 2001 (CORDROGUE 67 Council of the European Union, 2001). In those formal 
documents, ‘the EU Member States (…) are encouraged to ensure the availability of information on the 
five key epidemiological indicators and to identify and address possible problems in the production and 
dissemination of this information; the Council urges the Member States to give priority to the production 
and dissemination of information on the five key epidemiological indicators in a comparable form; (…) 
to provide the EMCDDA with information on the five key epidemiological indicators according to the 
EMCDDA guidelines (…); finally, the Council invites the Member States and the Commission, in close 
cooperation with the EMCDDA, to examine the best ways and means, in particular of a financial nature, 
to support the implementation of the five epidemiological indicators (…)’.
Since 2001, the data collection and reporting have been implemented and improved in most of 
the EU Member States, and TDI data are now routinely used in the EMCDDA’s analyses of the 
drug situation in Europe (see http: and www.emcdda.europa.eu/themes/key-indicators/tdi, 2011).
Objective, purpose and methodological implications
Why the TDI: what is its objective?
The objective of the Treatment demand indicator is to collect information in a harmonised and 
comparable way across all Member States on the number and profile of people entering drug 
treatment (clients) during each calendar year.
Although the name of the indicator is the ‘Treatment demand indicator’, it collects information on 
people entering treatment. This name will be maintained since the TDI is widely recognised as the 
instrument for collecting and reporting data on people entering treatment for their drug use inside 
and outside Europe, as an indirect indicator of the unobserved level of people that are potentially 
in need of drug treatment.
The TDI protocol prescribes which clients should be reported at European level, and the minimum 
common set of items each national monitoring system should be able to record and report to the 
EMCDDA for each client. 
Each national drug treatment monitoring system may include more items than those defined in the 
EMCDDA TDI protocol, according to national and local information needs. Also, the categories of 
the items collected at national level may be different from those requested in the TDI protocol, as 
far as it is possible to conduct a reliable conversion to the TDI categories (see below ‘Hierarchy of 
data needs: from clinical data to information of European policy relevance’).
17
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What is the collected information for: what is its purpose?
The primary purpose of the information collected by the TDI indicator is to gain insights into 
the characteristics, risk behaviours and drug use patterns of people with drug problems in the 
community, and to help to estimate trends in the extent (prevalence and incidence) and patterns of 
problem drug use; ideally, in combination with other drug indicators. This purpose is fundamental, 
since it determines the inclusion/exclusion criteria for the case definition of the TDI: the cases 
(drug clients) who should be reported to the EMCDDA should reflect as much as possible the 
characteristics of problem drug users in the community. 
This can best be achieved by recording the information soon after the user contacts the services, 
usually at the moment of admission/entry into treatment, after the professional assessment of the 
client’s characteristics. For the purpose of the indicator, the information collected on the client 
should reflect as much as possible his/her drug use patterns before contact with drug treatment; 
the treatment interventions on the client carried out before the registration should have no or 
limited influence on the recorded information (e.g. a person who enters treatment because he/she 
is injecting heroin could be recorded as not using heroin and not injecting if data collection and 
reporting is done when the client is already receiving some therapeutic intervention). Reporting the 
first treatment admission in the year generally will help to fulfil the indicator’s purpose. In addition, 
the information collected by the TDI indicator can help (together with other indicators and sources of 
information) to assess some parameters of drug treatment itself (provision, uptake, coverage). These 
aspects are being developed at present in the framework of a drug treatment monitoring strategy.
How the TDI purpose is achieved 
Drug treatment centres usually collect a considerable amount of information on their clients. This 
information is collected by professionals primarily to facilitate the therapeutic process, but also 
for administrative and management reasons at the local level, and for epidemiological purposes 
at the local, national or international levels. Some of the collected information will not be made 
available outside the treatment centre, some will be passed on to regional or national bodies 
and, finally, a limited part of the information will be collated at European level, following the 
procedures and definitions of the EMCDDA TDI protocol.
Drug treatment centres represent a fundamental information source to gain insight into drug use 
and problem drug use, since problem drug use is difficult to quantify and describe. Problem drug 
use has a relatively low prevalence in most EU Member States and is often socially stigmatised 
and, therefore, difficult to capture. 
18
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However, it should be borne in mind that not all problem drug users are in contact with treatment 
centres. Some users may not be in contact with any service (e.g. some socially integrated cocaine 
or cannabis users, some very marginalised heroin users) or they could be in contact with services 
that, for different reasons, may not collect information from their clients, or do not report it to 
national monitoring systems (e.g. private psychiatrists, web-based programmes or, in some 
countries, general practitioners or low-threshold agencies). 
Therefore, conclusions on problem drug use in the community based on data collected by the 
TDI should be drawn with caution, in particular when changes are small and/or based on limited 
numbers of clients. In addition, the availability of services, changes in service provision and the 
coverage of the reporting system must all be taken into account. Furthermore, interpretation of TDI 
information will benefit considerably from cross-validation with other indicators (e.g. drug-related 
deaths, law enforcement indicators) and ad-hoc studies (e.g. qualitative studies on street samples, 
studies and reports from other drug services not covered). 
Despite all these caveats, in many EU countries the TDI reports information from a considerable 
number of problem drug users (in some cases over 50 % of the overall estimated number of 
PDUs). This makes the indicator a strong and often the main, source of information on the 
population of problem drug users. In countries where a significant share of the PDU population is 
captured by the TDI reporting and the use and risk patterns of those not reported do not diverge 
substantially from those who are reported, the basic findings of the indicator can be considered 
robust, in particular if observations are consistent over time. Where it is known that subgroups of 
problem drug users exist with use and risk patterns that diverge dramatically from the patterns 
observed in the TDI indicator, local and targeted studies may be necessary to capture their 
behaviour. Furthermore, if service availability and treatment policies remain without fundamental 
changes during a period of time, trends observed in the TDI can signal important developments in 
problem drug use (e.g. changes in injection behaviour, expansion of crack use, etc.). 
Finally, the data obtained through the TDI indicator are an essential component of different 
methodologies to estimate the prevalence of problem drug use, usually based on the combination 
of databases generated by different services using different computation methods. 
What additional challenges has the TDI faced in recent years?
In the last 10–15 years, opioid substitution treatment has expanded dramatically in many EU 
countries, although not in all of them. The treatment population in these countries includes 
19
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a growing proportion of clients who entered treatment for heroin problems and have remained in 
opioid substitution treatment (OST) for a long period of time. Therefore, there are a considerable 
number of clients in continuous, long-term substitution treatment, who do not re-enter treatment 
again. Cocaine, amphetamine or cannabis clients are less affected by this situation, but some of 
them can be also in other forms of long-term treatment. 
It has become therefore increasingly necessary to estimate the number of those people and the 
module on ‘Treatment prevalence’ was conceived and tested in the past to assess the number 
and basic characteristics of this group of clients. This information will be collected in a separate 
voluntary module and is still in a developmental phase in the framework of a new strategy for 
data collection on treatment, which will include treatment availability, organisation and quality 
(the EMCDDA treatment monitoring strategy will be finalised by the end of 2012). Several 
countries are not currently able to compute the information that will be included in this module, 
as it requires a tracking system that allows the status of each client as ‘being in treatment or not’ 
to be determined, whereas the TDI itself is only designed to count treatment entries. At the same 
time, clients in continuous treatment (most of whom are opioid users) are in a special situation, 
as many of them are no longer using illegal opioids, though they may be using other drugs. 
Interpretation of this information regarding estimation of prevalence and patterns of problem 
drug use is particularly complex. But even considering the relevance of this new challenge, the 
core objectives of the TDI remain the same, and mainly concern the assessment of the number 
and characteristics of people with problems related to their drug use who enter drug treatment 
services during the calendar year. 
TDI implementation 
TDI data are collated at national level, often following a long process from treatment centre to 
regional level and from regional to national level. Then data are transmitted to the national focal 
points (NFP), which are the national agencies nominated by each government as the bodies 
responsible for providing the most up-to-date available information on drugs and drug addiction. 
National TDI data are then sent in aggregate form to the EMCDDA, according to the data 
reporting forms agreed by NFPs and the EMCDDA. 
From the late 1990s until 2011, the provision of treatment demand data to the EMCDDA has 
been implemented in most European countries. In 2000, the 15 countries that were Members 
of the European Union reported TDI to the EMCDDA, but data completion and data quality 
20
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was variable. Since then, data reporting has been progressively extended and data quality 
significantly improved. 
In 2010, the EMCDDA received data from 29 countries (27 EU Member States plus Turkey and 
Croatia) and since 2011, Norway will also send its data to the EMCDDA. The data were reported 
on the basis of TDI Protocol 2.0 and collected using the ‘Fonte’ (1) online tool.  
The data reported up to 2011 mainly cover outpatient and inpatient treatment centres. In the 
10 years since its implementation, it has proved difficult in most countries to collect information 
from other types of treatment centres. 
Most countries send almost all data required by the EMCDDA, but some limitations still remain 
regarding specific variables, which may change according to country. Data are still collected on 
other types of treatment centres, and efforts will be made to extend the data collection, where 
possible, to other services where drug users represent a relevant group of the clients.
The level of harmonisation is sufficiently good to enable comparability across countries, even 
though caution should be made in data interpretation, due to country differences in the drug 
treatment systems and variability in implementing some TDI definitions.
In 2009, a specific system to assess the quality of the EMCDDA Key indicators data, including 
TDI, was approved by the European Member States and applied on the basis of data reported 
for the year 2006. The system has shown substantial progress in TDI implementation and data 
comparability, even if some areas still need further improvement.
In 2006, a separate module of the TDI was field tested to report data on people ‘in continuous 
treatment’. The data collection has been maintained as a pilot data collection during several 
years. It is now included in the current version of the TDI protocol, as a separate module to be 
further developed and finalised.
The TDI has also been increasingly utilised over the last 10 years as an example and benchmark 
for countries and international organisations outside Europe, through presentations and training 
activities; in some cases, the instruments have been adopted as the main tool for collecting drug 
treatment data. This particularly concerns countries in the process of joining the European Union, 
the EU bordering countries and other international organisations (e.g. CICAD). 
(1) Fonte is the name of the online tool used by the EMCDDA to collect data from European countries.
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Regular collaboration has been maintained with global organisations working in the drugs area 
(UNODC and WHO). A joint publication on data collection on drug treatment demand was 
launched in 2006 as part of the UNODC toolkit series (UNODC, 2006).
Even though much progress has been made, some limitations in data quality still exist and 
improvement should be made in drug demand data collection and reporting, especially from 
a European perspective. 
General principles of TDI protocol 3.0
The TDI protocol 3.0 is based on some general principles, which should guide the data reporting 
from the countries to the EMCDDA and data analysis at European level. The EMCDDA and 
the European experts agreed on the following principles as the basis for implementing the 
TDI protocol 3.0. 
Monitoring versus research/ad-hoc studies 
Data monitoring differs from research and ad-hoc studies. Monitoring implies data collection 
of a limited set of information in a regular and systematic fashion, allowing the identification of 
changes over time. The need for more specific information is better addressed through ad-hoc 
projects and research. The TDI can only explore basic information and guide the exploration 
of further investigations based on general findings (e.g. social exclusion, patterns of drug use, 
outcome evaluation). Research projects can be based on questions emerging from the TDI, but will 
be built in different places and in a different format and only by those experts interested in a more 
in-depth analysis.
Hierarchy of data needs: from clinical data to information of European policy 
relevance
It is always important to clearly distinguish between the needs for data collection at different levels: 
local, regional, national and European. The information needs are different, since the level of 
detail necessary at the different level varies; it starts from detailed information collected for clinical 
purposes, to information useful to plan and evaluate interventions at treatment centre level, to data 
for planning treatment centres at local level, to more general information for regional, national and 
European plans on drugs and for the assessment of long-term results (Donmall, 2003).
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Figure 1: The TDI data collection flow — from local to European level
The EMCDDA information needs to provide the minimum common denominator of reporting for 
all countries. The data collected and/or reported may differ at different levels according to the 
different needs.
Referral, client details, initial assessment
clinical management, full assessment
[prescriptions, interventions]
outcomes
Local 
health authorities
National authorities
EMCDDA
TDI
AgencyAgency Agency AgencyAgency Agency
National
Regional
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Data reporting versus data collection
Data collection and data reporting are two distinct actions, happening at different levels and for 
different purposes. 
The data reported from each country to the European level is a pre-defined set of outputs 
obtained from the TDI national treatment databases. Those outputs may commonly be obtained 
by modifying data extraction routines and can be made without changing the TDI protocol itself 
and the underlying national, regional, local databases, commonly through modification of the 
data extraction routines. Adaptations of the reporting form may however require time and some 
changes to the software in a shared process with the involved partners. The focus of reporting 
to the EMCDDA under TDI Protocol 3.0 has moved away from the distinction based on the type 
of treatment centre; this switch should in principle not have implications for data collection at 
national level.
Individuals versus treatment episode
A treatment demand data reporting system can be based on the number of treatment episodes an 
individual receives during a certain period of time or on the number of individuals entering drug 
treatment during a certain period of time. The American drug treatment monitoring system, the 
Substance Abuse and Mental Health Services Administration (SAMHSA), for example, records the 
treatment episodes that an individual has initiated during one year. 
On the other hand, the TDI Protocol 3.0 is based on reporting information on each individual 
entering drug treatment during the calendar year, and does not count any person more than 
once during the time period. If a person has followed more than one treatment episode during a 
reporting year, only one case is reported.
A treatment episode has been defined as the ‘period of service between the beginning of 
treatment for a drug (…) problem and the termination of services for the prescribed treatment 
plan’ (SAMHSA, 2009), which also implies that ‘a client may attend one or more modalities/
interventions (or types) of treatment during the same episode of treatment. A client may also have 
more than one episode in a year’ (Manchester University, 2010). Consequently, the TDI protocol 
3.0 defines what is considered a ‘treatment episode’ for the purpose of TDI reporting in the 
section on ‘case definition’ (see below). 
24
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This principle has implications at both national and European levels. At national level, methods for 
controlling and avoiding double counting should be implemented within the country on the drug 
information system. At European level, it implies that the figures referring to different client groups 
will sum up to one single total number. 
Treatment incidence versus treatment prevalence
The TDI aims to capture the situation of the clients at the moment of their entry into treatment, 
as the best approximation of the characteristics of problem drug users. 
Over the last two decades, the number of clients who remain continuously in treatment over 
several years, especially in the context of long-term opioid maintenance treatment, has 
continuously increased in Europe. In 2006, work was started to document this through the 
development of a module on ‘treatment prevalence’. 
The module is separate from routine TDI data collection and has no practical implications for 
the TDI registration of treatment entries. The module is under development and presented in the 
Annex. It will be finalised in the context of and in collaboration with the EMCDDA Treatment 
Monitoring Strategy by the end of 2012.
Changes in definition and implications for past data
Changes in some definitions in TDI protocol 3.0 may have some effects on the reported data. 
Concerning past data, countries are not requested to report new data for previous years. From the 
analysis already carried out, the impact of the changes on the final results does not seem to be 
substantial in most countries; however, the effects of the changes will be carefully considered.
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Chapter 2
Guidelines
Definitions
Case definition
A case is a client who starts a drug treatment episode (2) at a treatment centre (3) during the calendar 
year: 1 January to 31 December for problems created by his/her drug use. 
A client should be reported only once during the calendar year: if, for any reason, the client is 
registered more than once at national level, the duplications should be removed as far as possible 
according to the existing technical tools at national level for reporting to the EMCDDA. The first 
treatment episode in the year should be reported. 
Purpose
To identify in a reliable way people with drug problems entering treatment and assess their 
problems, drug use patterns, health and social risks, with the purpose to use the information as an 
indicator of problem drug use patterns and trends.
Inclusion criteria
 ▯ A person who has started a drug treatment (as defined below under the definition of drug 
treatment) between 1 January and 31 December. 
 ▯ If a person has started more than once during the reporting year, only the first treatment 
episode (see below definition of treatment episode) should be reported to the EMCDDA.
Exclusion criteria
 ▯ A person who contacts a treatment centre on behalf of a drug user, but who is not a drug user.
 ▯ A person with problems due to his/her personal relationship to a drug user, but who is not 
a drug user him/herself.
(2) See below the definition of drug treatment and treatment episode for the purpose of this protocol.
(3) See below the definition of treatment centre for the purpose of this protocol.
28
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 ▯ A person who has already been reported once in the same centre or in another centre, during 
the calendar year. 
 ▯ A person who initiates a treatment activity/procedure in parallel to an ongoing treatment. 
This may be a component of treatment that has already been reported (in the year or in 
previous years), such as psychotherapy in parallel to an ongoing opioid substitution treatment, 
or an additional treatment.
 ▯ A person who initiates a treatment activity/procedure as a continuation of an ongoing 
treatment that has already been reported (in the year or in previous years), such as an 
inpatient detoxification requested after a two-year substitution treatment.
Methodological considerations 
It is recommended that double counting of the same client is avoided whenever possible at 
different levels and according to existing technical tools at national level: between regions or 
geographical/jurisdictional areas of the same country; between treatment centres, including 
treatment centres of a different type and within the same centre. In order to avoid counting the 
same client more than once during the reporting year, a technically ideal solution would be to 
have a central national register of drug clients with every client having a unique identifier, which 
would allow duplicates to be removed when data are reported. But the ideal technical option 
is not possible in a number of countries for administrative, economic or legal reasons. In those 
countries, feasible procedures to minimise the eventual double counting of cases should be put in 
place. The most basic option is that the treatment organisation should perform an internal check 
(within the same treatment centre) to see if there have been prior treatments. However, in addition 
to this, it might be necessary to ask the client if he/she has ever been in treatment before, as they 
could have been treated in other centres in the same period. An additional option in place in 
some countries is to control double counting at regional level through regional reporting systems 
and databases. This might avoid most double counts, as the administrative organisation of health 
and social services in many countries makes it difficult to be in treatment in different regions 
simultaneously (see also ‘Double counting’ in Chapter 3).
A graphical presentation is provided in Annex I.
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Drug treatment
Drug treatment is defined as an activity/activities which directly targets people who have problems 
with their drug use and aims to achieve defined objectives with regard to the alleviation and/or 
elimination of these problems, provided by experienced or accredited professionals, in the framework 
of recognised medical, psychological or social assistance practice.
This activity often takes place at specialised facilities for drug users, but may also take place in 
general services offering medical/psychological help to people with drug problems (see also 
‘Treatment centre’).
Purpose
This definition is rather broad, to include a wide range of different users with problems related 
to their drug use. It has to be recalled that the purpose of the TDI is primarily epidemiological, 
aiming to collect information on people with significant drug problems.
Inclusion criteria
 ▯ Interventions whose primary goal is detoxification 
 ▯ Interventions whose primary goal is abstinence
 ▯ Substitution treatment
 ▯ Specialised/structured longer-term drug programmes 
 ▯ Interventions aimed at reducing drug-related harm if they are organised in the framework of 
planned programmes 
 ▯ Psychotherapy/counselling
 ▯ Structured treatment with a strong social component
 ▯ Medically assisted treatment 
 ▯ Non-medical interventions inserted in planned programmes 
 ▯ Specific treatment in custodial settings towards drug users. 
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Exclusion criteria
 ▯ Sporadic interventions not included in a planned programme
 ▯ Contacts in which drug use is not the main reason for seeking help
 ▯ Contacts with general services involving requests for social assistance only
 ▯ Contacts only by telephone or letter 
 ▯ Contact with the family or other persons who are not the drug users him/herself only
 ▯ Imprisonment, per se
 ▯ Treatment by Internet only
 ▯ Services providing needles exchange only.
Methodological considerations 
The data should be as complete as possible; that means that all available data on persons with 
drug problems entering drug treatment as defined above — inclusion criteria — should be reported.
Start of treatment
Start of treatment is considered as the earliest formalised face-to-face contact(s) between the client 
and the centre. During this (these) contact(s), it should be possible to identify the client (avoidance of 
double counting) and to assess the client’s characteristics and needs related to their drug problem.
Depending on the type of centre, these requirements should be fulfilled after the first contacts —
possibly one to three contacts — between the clients and the therapist (in addition to possible 
contact with administrative staff). 
An indicative criterion of up to three face-to-face contacts is proposed, but countries should 
have the possibility to apply certain flexibility, according to their reporting practices. In the 
methodological information, it is important to report when the client is registered to be reported to 
the EMCDDA data.
If a client starts more than one treatment during the reporting year, only the first treatment episode 
should be reported to the EMCDDA, as mentioned above. 
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Purpose
The data reported in the first contacts between the treatment centre and the client aim to obtain 
recent information on the social profile of the drug client and of his/her patterns of drug use in the 
period prior to treatment.
Inclusion criteria
 ▯ A client who has face-to-face contacts with the treatment centre at an initial stage of treatment 
(usually between one and three contacts).
Exclusion criteria
 ▯ Contacts happening in a late stage of treatment (usually after the third or more contacts 
between the treatment centres and the client). 
 ▯ Contacts other than face-to-face contacts (telephone, Internet, etc.).
Methodological considerations 
Recording procedures differ between countries. This variable should ensure a certain 
harmonisation in the recording procedure across the countries and should guarantee that the 
basic data on the client can be recorded.
The number of contacts with the client which allows the countries (treatment centre, etc.) to report 
the data into the TDI protocol should be specified in the methodological information.
See also Table 1: Case definition — graphical description, in Annex I.
End of treatment
Treatment is considered to be ended either when there is a formal conclusion (agreed or not) or when 
the client stops attending the treatment centre or dies. 
The reasons for the end of treatment (‘treatment end’) may be related to dropping out of 
treatment, death, an explicit decision to abandon the treatment by the client or a termination 
of the treatment programme established by the centre (see also the module on Treatment 
prevalence).
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Purpose
The TDI protocol focuses on the ‘treatment entry’ and does not aim to collect data on treatment 
end. Data collection on treatment end is necessary for two operational reasons:
 ▯ Treatment end is directly linked to the TDI case definition and the decision of when a 
subsequent treatment should be recorded. The assessment on whether a previous treatment is 
finished is done at the moment of each treatment entry. 
 ▯ Treatment end information is related to the ‘Treatment prevalence’ module; it enables the 
identification of clients who are still in treatment from one year to the next or have concluded 
a treatment for any reason.
 For that reason, the information concerning the end of treatment does not aim to measure the 
treatment outcome, but only to assess whether a person is still to be reported as a treatment 
client or not. 
Inclusion criteria
Treatment is considered to be ended when:
 ▯ a professional has discharged the client;
 ▯ a client has explicitly decided to conclude the treatment;
 ▯ a centre/professional decides to terminate the treatment for reasons not related to the conclusion of 
the treatment, but for other reasons, such as not complying with treatment, breaking regulations, etc.;
 ▯ the client dies;
 ▯ the client has no contact with the treatment centre. It is recommended to consider a treatment 
finished after six months of no contact between the client and the treatment centre; however, 
countries vary greatly in the definition of the end of treatment. If countries have a different 
period for considering a client out of treatment (drop-out), the treatment can be considered 
ended according to the national rules. Countries should indicate the time for the end of 
treatment in the methodological specifications.
Exclusion criteria
Treatment is not considered concluded when:
 ▯ a client moves in the treatment system from one centre to another centre because he/she is 
referred in the framework of the same treatment episode (sometimes called ‘shared care’);
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 ▯ a client finishes one treatment activity and starts a new treatment activity as part of the same 
treatment episode; 
 ▯ a client still has contacts with the treatment centre within a period of six months or earlier 
(according to the period defined in the national rules as treatment drop-out).
Methodological considerations
The countries should state in the methodological information what the period for considering a 
client dropped out of treatment is. The rule of six months should be followed as much as possible. 
Treatment episode
A treatment episode is defined as the ‘period of service between the beginning of treatment for a 
drug (…) problem and the termination of services for the prescribed treatment plan’.
Drug treatment is a complex process, and often different therapeutic activities/procedures have 
to be delivered in parallel or consecutively, sometimes for a long period of time (e.g. counselling, 
psychotherapy, substitution treatment, other pharmacological treatments, outpatient or inpatient 
detoxification, longer-term residential care ...). ‘A client may attend one or more modalities/
interventions (or types) of treatment during the same episode of treatment. A client may also have 
more than one episode in a year’ (Manchester University, 2010) (SAMHSA, 2009).  
Purpose
To determine when a client is undergoing the same treatment process and therefore to determine 
whether a client needs or does not need to be notified again for the purpose of the TDI indicator. 
Inclusion criteria
 ▯ All the activities/procedures delivered to a client to address the drug problem that caused the 
treatment entry, as far as they are done in an organised/planned way. These activities may be 
delivered over a long period of time, and in the same premises or in different premises. They can 
follow an initial established plan or may be modified according to the client’s needs and evolution.
 ▯ If the process of treatment is formally finished or the client drops out of treatment (4), and 
subsequently the client is admitted again to treatment, a new treatment episode admission is notified.
(4) See definition of end of treatment.
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Exclusion criteria
 ▯ A single activity in the framework of a set of planned/organised chain of interventions is not 
considered as a treatment episode.
Treatment centre/programme
A drug treatment centre/programme is any facility that provides drug treatment, as defined above, to 
people with drug problems. Treatment centres can be specialised centres, focusing on the treatment 
of drug users, or included in bigger centres targeting different client groups (e.g. mental health 
patients, alcohol users, etc.). They can also be based within centres that are medical or non-medical, 
governmental or non-governmental, public or private. 
Purpose
To identify the broad range of facilities where a client is entering drug treatment, regardless of the 
type of interventions received. As the purpose of the indicator is identification of clients with drug 
problems, the type of facility is not a determinant factor. 
As explained in detail in the methodological considerations below, it is important to underline that 
for the previous TDI protocol version 2.0, detailed data were reported by type of treatment centre. 
In the current version of the protocol, the data will be reported in one template. 
The type of treatment centre will not be the focus of data reporting. In the reporting forms, there 
will be few tables where the breakdown by type of treatment centre should be reported.
Centres to be included 
The following types of treatment centres are defined in the TDI:
 ▯ outpatient treatment centres/programmes;
 ▯ inpatient treatment centres/programmes;
 ▯ treatment units in prison/programmes;
 ▯ general practitioners;
 ▯ low-threshold agencies/programmes;
 ▯ other types of treatment centres/programmes (please specify which type of centres/programmes).
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Definitions of the types of treatment centre
(a) Outpatient treatment centres are defined as treatment facilities where the clients are treated 
during the day (and do not stay overnight). They include public or private centres/clinics which 
may open in the evening but where the opening time excludes the night. 
(b) Inpatient treatment centres are defined as centres where the clients may stay overnight. 
They include therapeutic communities, private clinics, units in a hospital and centres that offer 
residential facilities. Clients should be reported as clients entering inpatient treatment centres 
when the first contacts between the client and the centre are happening in the inpatient centres 
and the TDI data are registered in those treatment facilities.
(c) Treatment units in prison are defined as those services that deliver specific services to prisoners 
because of their drug problem. They can include:
 ▯ units specialised in drug treatment with a dedicated physical space inside the prison;
 ▯ professionals (external or internal to the prison) who provide a package of interventions 
aiming to treat or reduce drug related problems of drug users in prison.
(d) General practitioners are medical practitioners who treat acute and chronic illnesses and 
provides preventive care and health education for all ages and both sexes. They may treat drug 
users for their drug problems, in some cases in liaison with outpatient or inpatient drug services, 
and some of them may have a specific training on the treatment of drug users.
(e) Low-threshold agencies are centres/programmes aiming to prevent and reduce health-related 
harm associated with drug dependence, in particular the incidence of blood-borne viral infections 
and overdoses, and to encourage active drug users to contact health and social services. 
(f) Other types of treatment facilities are all treatment centres that provide drug treatment 
as defined above. In the case of the use of the category ‘other types of treatment facilities’, 
the type of treatment facility that is reporting data should be described and specified in the 
methodological specifications.
Centres/programmes to be excluded
 ▯ Any other type of treatment facilities, when they are not involved in drug treatment as defined 
above (definition of treatment)
 ▯ Centres/programmes for information dissemination only
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 ▯ Centres/programmes only concerned with needle/syringe exchange only
 ▯ Sporadic interventions towards drug users in prison are not included (e.g. information, needle 
provision and exchange only, etc.) as defined in the exclusion criteria for drug treatment
 ▯ Hospital emergency rooms
 ▯ General social care facilities, not targeting drug use.
Methodological considerations
Data will be reported to the EMCDDA with a focus on the clients themselves, their characteristics 
and their patterns of drug use, particularly the primary drug. The treatment centre/programmes, 
that previously were the basic stratification of the reporting, will only be one of the reported 
variables. The focus on the clients is related to several reasons:
 ▯ The purpose of the indicator is epidemiological and focuses on the number and characteristics 
of clients entering drug treatment as an indirect indicator of problem drug use.
 ▯ 10 years of European data collection show that 80 % of clients reported to the EMCDDA 
enter treatment in outpatient centres, while the other types of centres (excluding prison) are 
usually not the point of entry, but are used in subsequent phases of the treatment programme.
 ▯ In a number of countries, general practitioners, low-threshold services and other types of 
treatment source either do not play a substantial role in the provision of drug treatment as 
defined in the protocol (though they can provide very valuable help to drug users), or it is not 
possible to collect data from these sources. Consequently, data is available from only a few 
countries, making it difficult to analyse them at European level.
 ▯ Only a few specific analyses are useful by type of treatment centre. It is difficult to make 
detailed comparison by type of treatment centres, due to national differences in treatment 
organisation.
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Primary drug
The primary drug is defined as the drug that causes the client the most problems at the start of 
treatment. This is usually based on the request made by the clients and (or) on the diagnosis made 
by a therapist, commonly using international standard instruments (e.g. ICD-10; DSM-IV (5), ASI) or 
clinical assessment. This item is of central importance and it should be collected for every client.
Purpose
To identify the clients’ primary drug problem, assessing their profile and trends over time in drug 
use patterns. This variable allows information to be kept on the most relevant problems for the 
drug users from an epidemiological point of view. 
Inclusion criteria
 ▯ The primary drug is the drug that leads to the most serious problems (health, mental, social 
problems, etc.) for the client
 ▯ The primary drug is the main reason the client has entered treatment
 ▯ The primary drug may include any drug misused by the client but not used in accordance with 
a medical prescription
 ▯ The primary drug includes any drug specified in the item list of the primary drugs presented 
below.
Exclusion criteria
 ▯ Alcohol can only be recorded as a secondary drug accompanied by a primary drug (see 
Secondary drug section)
 ▯ Tobacco 
 ▯ All psychoactive medicines and drugs used exclusively for medical treatment under a medical 
prescription and according to medical practice.
(5) It has to be noted that the DSM-IV is under revision and a revised version — DSM-V — should be 
available in the near future.
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Methodological considerations
The decision on the choice of a primary drug should be based on the diagnosis of the 
professional plus the request of the client. 
The criteria to select the primary drug have not changed and are consistent with the criteria for 
data reporting included in the TDI protocol 2.0. A new variable on polydrug use is is now added 
to provide complementary information, but not as a replacement.
If the exact drug is not known (e.g. amphetamines or MDMA and derivatives), the generic 
category (e.g. Stimulants other than cocaine) should be recorded.
The category ‘Not known’ should be used exceptionally.
Secondary drug
Secondary drugs are those drugs used in addition to the primary drug, and are substances that cause 
problems for the client and/or change the nature of the problem as assessed by the client and the 
therapist.
Purpose
To identify other drugs that cause problems for the clients. 
Inclusion criteria
 ▯ All drugs that can cause problems for the health and social condition of the client, but are not 
identified as the primary drug
 ▯ Alcohol.
Exclusion criteria
 ▯ Tobacco
 ▯ Substances that are used by the clients, but do not cause problems to his/her condition
 ▯ Medicines used under medical prescription and according to medical practice.
Methodological considerations
The secondary drugs should be substances used and creating problems for the clients. Up to four 
secondary drugs should be reported to the EMCDDA. However, countries have different recording 
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procedures and may record a different number of secondary substances. In that case, it is necessary 
to indicate how many substances are recorded for each client in the methodological information.
Polydrug use problem
Information on polydrug use problem is complementary and additional to the information on the 
primary drug. Existence of a polydrug use problem should always be assessed after the primary drug 
is determined, following the guidelines and the specific procedures.
Purpose
The polydrug use problem variable aims to assess whether a client is a problematic user of more 
than one drug at the same time, in a way that is very difficult to identify clearly one primary 
drug. This concept should be used in a very restricted approach as in the ICD-10, which defines 
polydrug use as multiple drug use to be used ‘when two or more psychoactive substances are 
known to be involved, but it is impossible to assess which substance is contributing most to the 
disorder’. The decision is fundamentally clinical, and it should be used in a restrictive way.
Inclusion criteria
 ▯ Clients that present a pattern of use where several substances are causing substantial problems 
simultaneously to the client and it is very difficult to determine what is the primary drug.
 ▯ This information should be collected only after a primary drug has been determined as 
previously under protocol 2.0, even with the known difficulties in some cases. Existing rules 
and procedures to select a primary drug should continue to be applied.
Exclusion criteria
 ▯ Clients using only one drug
 ▯ Clients using more than one drug, but only one causing problems 
 ▯ Clients using more than one drug that cause problems, but for whom it is possible to identify 
with some confidence which one is causing more problems. 
Methodological considerations
The use of multiple drugs per se does not constitute a polydrug use problem for the purpose of the 
TDI protocol. A client is defined as a polydrug problem user when more than one drug creates 
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problems systematically to the client in a way that it is difficult to determine clearly which drug 
causes more problems.
Rationale of the approach adopted in TDI protocol 3.0
Polydrug use can be conceptualised in different ways, including use of different substances in the 
same timeframe (e.g. in the last 30 days) but without a relevant pharmacological interaction, or it can 
imply simultaneous use of several substances mixed together (e.g. heroin and cocaine in the same 
injection) or within a short period of time. Also, it may imply a regular replacement of a substance by 
another depending on availability (e.g. opioids and benzodiazepines).
A simple replacement of the ‘primary drug’ concept might imply a very high risk of fundamental 
divergences in data collection and reporting by countries, making data not comparable and 
almost impossible to interpret. Also, there is a considerable risk that current historical series are 
totally discontinued. Some countries that attempted to implement ‘polydrug’ data collection found 
considerable difficulties. Finally, most European and not European countries have been able to 
identify a primary drug for years, despite the known difficulties. Any modification of this concept has 
to be done with extreme care as it may imply a fundamental change for all analysis, trends and other 
methodologies based on TDI data.
An approach where a primary drug is not indicated would imply a high risk of divergence by 
countries in data reporting and loss of information. Therefore, the approach adopted allows the 
collection of complementary information on polydrug use problems, while maintaining the concept of 
primary drug and consistency with existing data and between countries.
This situation is not unique for treatment data. Similar questions have been raised in mortality data. 
WHO, in its 2002–03 update of ICD-10 classification for drug-related deaths, addressed the same 
problem and a priority list of drugs to codify the more dangerous drug was established (in case the 
certifying doctor cannot reach a conclusion). 
See EMCDDA DRD protocol 3.2
•	 http://www.emcdda.europa.eu/html.cfm/index107404EN.html (Annex 7, page 64) 
Or the WHO list of ICD-10 updates
•	 http://www.who.int/classifications/icd/icd10updates/en/index.html
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HIV or HCV testing uptake 
HIV and HCV testing uptake represent basic information on the access to care of drug treatment 
clients (mainly those injecting drugs). 
Purpose
The information is useful to cross and complement data with the client’s information on injecting 
behaviour (collected in the TDI on one hand, and from other sources of infectious diseases 
information — Standard Table 09 — on the other hand). The final aim is to have a more complete 
and reliable picture on the level of testing of infectious diseases among treatment clients.
Methodological considerations
It is very important to know the injecting status of the client (ever vs never) and data should always 
be provided, broken down by injecting status and by drug.
The consistency of the information reported through the TDI indicator and information reported in 
the DRID indicator will be assessed in detail, and in cooperation with countries.
Needle/syringe sharing
There are several patterns of equipment sharing (needle, syringes, filters, drug solutions, lending/
borrowing equipment, sharing with partner, with friends, etc.) that represent important risk behaviour. 
Needles and syringe sharing is one of these risk behaviours.
It is not possible to capture all possible patterns of drug equipment sharing in a European 
monitoring system. At national or local level, much more detailed information can be collected, 
in particular where infectious diseases have a high prevalence or there is a risk of increasing 
prevalence. For that reason, it is only requested to report the information on needles/syringes 
sharing to the EMCDDA. More detailed information at European level is reported through other 
instruments (notably Standard Table 09).
Purpose
To collect basic information on important risk behaviour (needles/syringe sharing), which can lead 
to infectious diseases.
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Inclusion criteria
 ▯ All clients who have ever injected drugs.
Exclusion criteria
 ▯ All clients who have never injected.
Methodological considerations
Information should refer to ever injectors of any drug.
Opioid substitution treatment (OST)
Opioid substitution treatment is a long-term intervention with the use of an agonist substance with the 
goal of reducing or eliminating the use of an illicit opioid drug, or to reduce harm from a particular 
method of administration and the attendant dangers for health. 
Purpose
To better determine the level of accessibility of substitution treatment. To check whether a client 
re-entering treatment is/has been already in substitution treatment before. It will also provide 
information about lifetime OST among those entering treatment for another problematic drug use 
and time spent since the first OST.
Inclusion criteria
 ▯ Clients who have already been treated in year(s) prior to the reporting year.
Exclusion criteria
 ▯ Clients who have never been treated before the reporting year. 
Methodological specifications 
It is important to check if the client is undergoing substitution treatment with a substance and 
whether he/she is also reported as misusing the same or another substitution substance. This will 
be useful as validation information and to check the appropriateness of the treatment.
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Item list
1. Treatment centre type
1. outpatient treatment centres/programmes
2. inpatient treatment centres/programmes
3. treatment units in prison/programmes
4. general practitioners/programmes
5. low-threshold agencies/programmes
6. other (please specify which type of treatment centre/programme)
99. not known.
Methodological specifications
The six types of treatment centres presented above are the most common types for which clients 
are identified and data reported; they are also the most common points of entry into the treatment 
system.
Treatment units in prison represent an important entry point for many drug users who would not 
appear in treatment otherwise. In addition, the issue of drug and prison currently represents a 
high priority issue in the European political agenda and deserves specific attention. 
For the definition of treatment and the classification of treatment centres that are not included 
in the three groups presented above, please see the section on definition of drug treatment and 
treatment centre.
It is noted that in the data reporting form, the breakdown by type of treatment centre will not be 
central and only a few breakdowns will be reported by type of treatment centre. 
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2. Year of treatment
/____________/
Methodological specifications
The starting date of treatment is essential for creating trend analyses over time and for separating time 
periods (treatment episodes) for reporting. This enables a dynamic analysis of the treatment data.
The month of treatment should not be reported to the EMCDDA, but must be recorded at national 
and treatment centre level in order to avoid the risk of counting the same person twice in the same 
reporting period.
3. Ever previously treated 
1. never previously treated
2. previously treated
99. not known.
Methodological specifications
See also definition of ‘first treatment’ in the section on definition for client never treated before the 
reporting year. If a client is entering treatment more than once in the same reporting year, only 
the first treatment episode should be recorded. Other previous treatments may refer to treatment 
undergone because of the use of any drug, which might be different from the current primary 
drug. Double counting should be avoided within the same country as much as possible, according 
to the possibilities of each country.
4. Source of referral
1. court/probation/police 
2. general practitioner
3. other drug treatment centre
4. other health, medical, or social service
5. educational services
6. self-referral, referral from family, friends, etc./no other agency/institution involved
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7. others (please specify)
99. not known.
Methodological specifications
The source of referral provides some insight into the pathway by which the client has reached 
drug treatment. According to the European analysis carried out in the last 10 years, it has been 
seen that it is relevant to understand what services other than drug services are involved in the 
referral to treatment. The objective of this variable is to understand the level of involvement of 
other agencies, health, social services and institutions in referring the client to treatment. Data 
on source of referral is also important to estimate the extent of treatment which is due to a legal 
obligation. The ‘Source of referral’ refers to the source that was most instrumental in referring the 
client to treatment.
5. Sex
1. male
2. female
99. not known.
Methodological specifications
Basic epidemiological information. 
6. Age at treatment start (in years)
Age: /___/___/
99. not known.
Methodological specifications
Basic epidemiological information.
7. Living status (with whom)
1. alone 
2. with the family of origin (parents, etc.)
3. with partner/children 
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4. with friends or other people (with no family relation)
5. in detention
6. in institutions/shelters (not detention)
7. others 
99. not known.
Methodological specifications
The primary purpose of the ‘with whom’ aspect of the living status is to indirectly assess the 
relational status of the clients. The situation refers to the prevailing situation of the client, if he/
she is living in more than one context in the same period. The living status refers to the current 
situation:  It refers to the 30 days before entering treatment.
8. Drug clients with children
1. not having children 
2. having children 
 2.1 not living with children
 2.2 living with children 
99. not known.
Methodological specifications
The item wants to assess if the clients have children and what is the living condition of drug users 
and children. Children include all ages of children, both biological and not biological. 
9. Living status (where)
1. stable accommodation
2. unstable accommodation and/or homeless
3. in detention
4. others 
99. not known.
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Methodological specifications
The ‘where’ aspect of living status stresses the stability of the living situation. Clients in unstable 
accommodation are clients who have lived in different places (friends’ home, street, shelters, 
etc.), moving from one place to another in the period prior to treatment entry. If a client is living in 
an institution, he/she should be reported in category 4 ‘others’ and the institution specified. The 
situation refers to the prevailing situation of the client, if he/she is living in more than one context 
in the same period. The living status refers to the current situation:  it refers to the 30 days before 
 entering treatment.
10. Labour status
1. occasionally employed
2. regularly employed
3. student
4. unemployed/discouraged
5. receiving social benefits/pensioners/house-makers/disabled
6. others
99. not known.
Methodological specifications
Labour status provides central information about the client’s economic and social integration 
and his or her daily life. The protocol follows Eurostat’s standards as much as possible to enable 
comparison with the statistics for the general population and to avoid overlapping categories 
(e.g. unemployed and inactive). The categories defined by Eurostat in the official statistics on 
labour status are the following:
 ▯ Employed: people performing of at least one hour of work (for pay, profit or family gain), 
during the last 30 days; 
o Occasional: when the job is infrequent, irregular or occurring in scattered instances;
o Regular: when the job is frequent, regular and/or with a written contract;
 ▯ Students: people attending a school;
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 ▯ Unemployed: people who are not working and actively looking for a job; Discouraged: 
people who are not working and not looking for a job, because they could not find a job;
 ▯ Receiving social benefits/Pensioners/House-makers/Disabled: people who are receiving 
benefits from social security for their pension or invalidity or are housekeepers.
 It refers to the 30 days before entering treatment.
11. Highest educational level completed
1. never went to school/never completed primary school (=ISCED 0)
2. primary level of education (=ISCED 1)
3. secondary level of education (=ISCED 2 and ISCED 3)
4. higher education (=ISCED 4 to 6)
99. not known/missing.
Methodological specifications
Education is an important socio-economic data category. A stricter compliance to ISCED (6) 
(International Standard Classification of Education) classification are recommended as well as 
the adoption of the country-specific conversion rules that are already implemented for providing 
education statistics at international level.
12. Primary drug (7)
1. Opioids (total)
 11 heroin
 12 methadone misused
 13 buprenorphine misused 
 14 fentanyl illicit/misused
 15 other opioids (please specify)
(6) It has to be remembered that the ISCED classifications are under revision; eventual implications of the 
revised version will be taken into account. 
(7) Note that several substances in the list can be produced illicitly (e.g. fentanyl or some amphetamines) or 
diverted from legitimate sources. For the purpose of this protocol, both sources are included.   
49
Chapter 2: Guidelines
2. Cocaine (total)
 21 powder cocaine (HCl)
 22 crack cocaine
 23 others (please specify)
3. Stimulants other than cocaine (total)
 31 amphetamines
 32 methamphetamines
 33 MDMA and derivatives
 34 synthetic cathinones
 35 other stimulants (please specify)
4. Hypnotics and sedatives (total)
 41 barbiturates misused
 42 benzodiazepines misused
 43 GHB/GBL
 44 other hypnotics and sedatives misused (please specify)
5. Hallucinogens (total)
 51 LSD
 52 ketamine
 53 other hallucinogens (please specify)
6. Volatile inhalants
7. Cannabis (total)
8. Other substances (total) (please specify which substance)
99. Not known.
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Methodological specifications
‘Primary drug’ is the drug that causes the most problems for the client, as defined according to the 
client’s request and (or) the professional’s assessment. 
This item should always be filled in, regardless of whether a client is subsequently considered to 
have a polydrug use problem (that will be additional information). 
Some new drugs are included in the Protocol. They are substances that have appeared in recent 
years in the drug market, and for which a non-trivial number of people has entered treatment for 
problems associated with their use. The classification does not follow a scientific classification of 
the substances according to their chemical principles or psychoactive effects (e.g. cocaine and 
other stimulants are separated), route of administration, or other scientific categorisations. Rather, 
a pragmatic classification is adopted, in order to help professionals working at drug treatment 
centres to record the data.
The substances included are only those which create problems to the client according to the 
client’s request and the professional’s assessment.
The grouping of drugs is not only done on the basis of pharmaceutical criteria but also 
considering the actual experience of drug professionals.
Other opioids include all the opioids not included in the previous categories (e.g. Polish heroin). 
The insertion of fentanyl among primary drugs includes both the substance produced in the illicit 
market and the medicinal product used outside the medical practice.
Any specification on the primary substance should be included in the methodological comments.
The following substances are excluded from the primary drug:
 ▯ tobacco;
 ▯ alcohol (included among the secondary drugs);
 ▯ drugs used for medical purposes under a medical prescription.
It refers to the 30 days before entering treatment, with the exception of clients who have been 
in withdrawal treatment, were drug-free or were in detention prior to treatment intake. In those 
cases, the reference period refers to the 30 days before withdrawal treatment, drug-free or 
detention.
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13. Usual route of administration of primary drug
1. inject
2. smoke/inhale
3. eat/drink
4. sniff
5. others
99. not known.
Methodological specifications
‘Injection of drugs’ represents a primary form of risk behaviour for drug users. It is of particular 
importance with regard to infectious diseases (hepatitis, HIV), as well as other diseases and 
injuries; the reduction of injecting behaviour is the aim of many harm reduction programmes. The 
‘Usual route of administration’ refers to the route of administration of the primary drug. 
‘Smoke/inhale’ refer to the use of the substance via pulmonary routes (via the nose or the 
trachea); they concern the substance taken in the form of vapour. ‘Sniff’ refers to the nasal route 
and to the substance in powder form. 
It refers to the 30 days before entering treatment, with the exception of clients who have been 
in withdrawal treatment, were drug-free or were in detention prior to treatment intake. In those 
cases, the reference period refers to the 30 days before withdrawal treatment, drug-free or 
detention.
14. Frequency of use of primary drug
1. daily 
2. 4–6 days per week
3. 2–3 days per week 
4. once a week or less 
5. not used in the last 30 days
99. not known.
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Methodological specifications
The frequency of use of the primary drug is an indicator of the severity of the drug use. 
It refers to the last 30 days before entering treatment, with the exception of clients who have 
been in withdrawal treatment, were drug-free or were in detention prior to treatment intake. In 
those cases, the reference period refers to the 30 days before withdrawal treatment, drug-free 
or detention.
15. Age at first use of primary drug (in years)
Age: /______/
99. not known.
Methodological specifications
The negative effects of drug use often increase over time. The duration of drug use can be 
calculated on the basis of age of first use and age at the start of treatment. Epidemiologically, 
age of first use is an indicator of age when risk of drug use starting is greatest. Tracking long-term 
trends may aid in the development of preventive activities.
16. Secondary drugs (8) 
1. Opioids (total)
 11 heroin
 12 methadone misused 
 13 buprenorphine misused 
 14 fentanyl illicit/misused
 15 other opioids (please specify)
2. Cocaine (total)
 21 powder cocaine (HCl)
 22 crack cocaine
 23 others (please specify)
(8) Same criteria regarding the origin of the substance (illicit production or diversion) as with the primary drug.
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3. Stimulants other than cocaine (total)
 31 amphetamines
 32 methamphetamines
 33 MDMA and derivatives
 34 synthetic cathinones
 35 other stimulants (please specify)
4. Hypnotics and sedatives (total)
 41 barbiturates misused
 42 benzodiazepines misused
 43 GHB/GBL
 44 other hypnotics and sedatives misused (please specify)
5. Hallucinogens (total)
 51 LSD
 52 ketamine
 53 other hallucinogens (please specify)
6. Volatile inhalants
7. Cannabis (total)
8. Alcohol as secondary drug (total)
9. Other substances (total) (please specify which substances)
99. Not known.
Methodological specifications
The substances included are only those that create problems to the client according to the client’s 
request and to the professional’s assessment. 
If a client does not use a secondary drug, this item should be left empty. 
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Up to four drugs may be reported. In the data reporting form, the maximum number of drugs 
reported by each individual should be indicated. 
For the purpose of reporting to the EMCDDA, the order of filling in secondary drugs will be 
according to their clinical relevance for the drug problem of the client. Only if this is not possible, 
the order of filling secondary drugs will be the following (if there is information collected): first 
substances used by injection, and then according to frequency of use. If none of the above is 
possible, the order will be that of the list of substances.
The exact criteria used should be explained in the methodological section of the reporting form.
Alcohol is included as a secondary drug. 
Tobacco and drugs used for medical purposes and under a medical prescription are excluded.
Other opioids include all the opioids not included in the previous categories, such as Polish heroin. 
It refers to the 30 days before entering treatment, with the exception of clients who have been 
in withdrawal treatment, were drug-free or were in detention prior to treatment intake. In those 
cases, the reference period refers to the 30 days before withdrawal treatment, drug-free or 
detention.
17. Polydrug use problem existing
1. yes
2. no
99. not known.
Methodological considerations
‘Polydrug use problem’ refers to when two or more drugs are involved in the drug problem of the 
client at the same time and it is very difficult to assess which was the primary drug that caused 
the treatment entry. This concept will be used in a very restricted approach as in the ICD-10 
(see Definitions).
This item should always be filled in, even if only one drug is used (or the primary drug can be 
established with reasonable accuracy among several substances used) and the client is not 
a polydrug user (in that case, reply No to the question). 
However, even in the case of a client for which a primary drug is very difficult to determine, 
always a primary drug should be chosen, following the indications provided in the guidelines 
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and the concrete implementation procedures used at national level (e.g. client request, 
clinical assessment, standard scales of dependence, frequency of use, agreed hierarchy of 
substances, etc).
It refers to the 30 days before entering treatment, with the exception of clients who have been 
in withdrawal treatment, were drug-free or were in detention prior to treatment intake. In those 
cases, the reference period refers to the 30 days before withdrawal treatment, drug-free or 
detention.
18. Opioid substitution treatment (OST)
1. never been in OST
2. ever been in OST 
99. not known.
Methodological specifications 
OST is commonly referred to as ‘substitution treatment’. A substitution treatment is defined as ‘the 
administration of thoroughly evaluated opioid agonists; this is done by experienced or accredited 
professionals, in the framework of recognised medical practice, for achieving defined treatment 
aims’. This treatment is often provided in combination with psychosocial assistance. This variable 
will help to better determine the level of accessibility of substitution treatment and provide 
information about lifetime opioid substitution treatments among those entering treatment for 
another problematic substance use.
Only clients who have been previously treated should be included. 
19. Age at first opioid substitution treatment (OST) (in years)
1. Age at first OST:  /______/
99. Not known.
Methodological specifications 
This variable in combination with data on age at first primary drug, age at first injection will 
contribute to provide information about lifetime opioid substitution treatments among those 
entering treatment for a problematic substance use other than opioids. The item should be filled in 
only by people who have been in OST before the current treatment entry.
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20. Ever injected or currently injecting any drug 
1. never injected 
2. ever injected
 2.1 injected, but not in the last 12 months 
 2.2 injected in the last 12 months, but not in the last 30 days 
 2.3 currently injecting (in the last 30 days) 
3. don’t want to answer
99. not known.
Methodological specifications
This variable refers to injection behaviour regarding all drugs, not just the primary drug. This item 
identifies the injection of any drug; it gives a good indication of risk behaviour. This is of particular 
importance with regard to the transmission of infectious diseases (hepatitis, HIV) as well as other 
diseases and injuries and issues of harm reduction. Injection for medical purposes should be 
excluded (diabetes, etc.). 
21. Age at first injection (in years)
Age:  /______/
99.  not known.
Methodological considerations
This variable should only be filled in for people who have ever injected. If people never injected 
any drug, it should be left empty.
22. HIV testing 
1. never tested 
2. ever tested
 2.1 tested, but not in the last 12 months 
 2.2 tested in the last 12 months
3. don’t want to answer 
99. not known.
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Methodological considerations
The item concerns testing activities and can be useful information to be crossed with drug use 
behaviours (injecting, needle sharing). It is strongly advisable to verify the testing history as far as 
possible’. 
23. HCV testing 
1. never tested 
2. ever tested
 2.1 tested, but not in the last 12 months 
 2.2 tested in the last 12 months
3. don’t want to answer 
99. not known.  
Methodological considerations
The item concerns testing activities and can be useful information to be crossed with drug use 
behaviours (injecting, needle sharing). 
24. Needle/syringe sharing
1. never shared a needle or syringe
2. ever shared a needle or syringe
 2.1 shared but not in the last 12 months
 2.2 shared in the last 12 months, but not in the last 30 days
 2.3 currently shared (in the last 30 days)
3. don’t want to answer
99. not known. 
Methodological considerations
Information to be asked only if the client has ever injected. If the clients has never injected, the 
variable should be left empty.
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Methodological and ethical issues
Besides the general principles highlighted in the first part of the protocol, it is necessary to explain 
specific methodological issues that are important for data collection and reporting.
To contextualise the TDI data reported by each country, it is important to have access to 
methodological information. A space for specifications on methodology used to collect and report 
data is included in the EMCDDA data reporting form. A dedicated space for comments is included; 
it will be particularly important to use that space when country data diverge from the EMCDDA 
guidelines or have specificities which cannot be understood from the quantitative data alone.
Time reference period
The reference period for the whole protocol concerns the current situation of the client in the last 
30 days (1 month) before entering treatment. This is the general rule for all the variables included 
in the protocol, unless it is not applicable by default or differently specified. If not indicated, it 
means that it is not applicable, but usually this is understandable from the context of each item (e.g. 
ever injected, age at first OST, etc.). For drug-related aspects and in the case of clients who have 
been in withdrawal treatment, were drug-free or were in detention prior to treatment intake, the 
reference period refers to the 30 days before those events (withdrawal, drug-free or detention).
Patterns of drug use: drug of reference
The data on patterns of drug use — age at first use, route of administration, frequency of use — 
refer to the primary drug. The items ever injected and age at first injection refer to any drug. This 
is, however, specified in every item.
Coverage 
Information on data coverage is required in order to understand the context of TDI data in each 
country and its level of representativeness. 
First, the estimation of the TDI coverage should refer to those centres that are expected to report 
as part of the TDI reporting system. In addition, an estimate, even an approximate one, should 
be made of the extent to which the TDI reporting system covers the total treatment services in 
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the country. This will be influenced by the availability and organisation of the national treatment 
system and of the referral system, as well as by the drug legislation. 
Results from TDI data analyses show that there are both common features and substantial 
differences among the countries, probably due to national differences in the characteristics of the 
drug problem, in the treatment systems, and in the reporting systems and their data quality. Some 
differences are bound to be due to differences concerning which types of treatment facilities and/
or client groups the national systems cover. A specific EMCDDA project carried out in 2007–08 
(Iversen, 2009) on data coverage highlighted issues to consider when data on treatment demand 
are collected. A survey in some countries showed the need to have better information on treatment 
availability and capacity in order to understand the context of TDI data. This information is partly 
included in the methodological information and partly reported through other EMCDDA tools 
focused on treatment availability/capacity (Standard Table 24 and Structured Questionnaire 27). 
The final recommendations of the project highlighted the need to:
— include coverage assessment in more detail in the data quality assurance system for the TDI;
— encourage countries to develop systems for monitoring treatment facilities and treatment 
capacities;
—  encourage countries to design systems with obligatory reporting from outpatient and inpatient 
drug treatment agencies (centres/units), including capacity data reporting as well as existing 
TDI data.
Data quality 
Data quality is extremely relevant in the utilisation of drug-related data, particularly in a European 
data set, where information should be as comparable as possible across countries and consistent 
over time. However, the control of data quality is a complex activity, especially when it involves 
data from different countries reported in an aggregate form.
Treatment demand data provided by the countries are routinely validated when they are reported 
to the EMCDDA. Basic validation procedures are implemented regularly on data completeness, 
consistency, timeliness, problems in the numbers and figures which differ greatly from the 
general EU picture. Methodological information is also regularly checked to acquire an in-depth 
knowledge of the information system and the actual implementation of the methodological 
guidelines in the reported data.
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Besides the routine data quality control carried out every year, a specific system to assess the 
quality of data for all the key indicators was carried out in 2008. The system was applied to the 
TDI data and includes an assessment of aspects related to two areas of data reporting: process of 
reporting and data quality. The assessment of data quality was carried out in consultation with the 
NFPs and the TDI experts.
Concerning the process, the assessment concerned the following aspects: organisation of the 
reporting system, financial and human resources dedicated to the data collection, legal basis 
for data collection, data quality assessment, ongoing progress and main obstacles to TDI 
implementation. In the area of data quality, the evaluation focused on the availability of data at 
national level and data reporting at European level, harmonisation with the EMCDDA guidelines, 
timeliness, data coverage and internal data consistency. 
The results of that assessment have shown that most countries have made substantial progress 
in implementing the TDI guidelines in recent years, and the level of data comparability has 
substantially improved; however, some areas still need improvement, such as data coverage and 
harmonisation with European standards. Furthermore, the implementation of data quality in the 
countries may be limited by the scarce availability of financial and human resources.
Double counting 
In this context, ‘double counting’ refers to the fact that a client may be registered more than 
once in a treatment-monitoring database in a given year. This may be due to several reasons, 
including lack of communication between treatment centres, absence of a unique system to allow 
for cross-checking, and others. Double counting causes the total number of treated persons to be 
overestimated. 
Based on the guiding principle that what should be counted are individuals and not episodes, 
double counting should be avoided as much as possible at any level, from the treatment centre, 
to local, regional, national or international level. Of course, this rule will be applied considering 
the level of actual feasibility and limitations at national, regional and local level (technological 
and methodological instruments, financial and human resources, legal framework, including legal 
obstacles due to data protection rules). 
Several techniques have been implemented in the countries (Origer, 1996), from the most 
common, such as controlling for double counting in a register through a unique identifier given for 
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the individuals (usually based on an algorithm which utilises the name and date of birth), to some 
quite sophisticated techniques, such as the use of digital prints (e.g. the Netherlands). 
In an ideal situation, the maximum level of control of double counting implies that the countries 
have a central register where they record all single individuals, with some form of unique identifier 
to avoid duplication. This register should fulfil all requirements to guarantee data protection. 
A second best option is the existence of a regional database that can control double counting to a 
considerable degree. If a central or regional register does not exist or is not possible to implement 
for several reasons, including legal, administrative, financial reasons, the treatment organisation 
should try to implement methods to perform data checking of prior treatments (e.g. electronically 
and/or asking directly to the client if he/she has ever been in treatment before and/or asking to 
other treatment centres that may have had previous contacts with the client).
According to the situation updated in 2008, the avoidance of double counting was found to 
be quite common among the EU countries, with only two countries having no or limited double 
counting control in place. Out of the 26 countries where such control exists, for nine, it operates at 
regional or treatment centre level and in 17, at national level.
Ethical issues and data protection
Where treatment of drug problems takes place, notes are taken on drug use and the clients’ 
strengths and weaknesses. Treatment steps are usually planned on the basis of a formal diagnosis 
or on an overview of problems requiring attention performed by a professional or a team of 
professionals. Aims are monitored continuously during treatment and the outcome is evaluated at 
the end. Information is primarily collected for the purpose of improving the care for clients.
Data collection and reporting, beside the clinical purposes, has the scope to obtain basic 
information on the epidemiological situation to support evidence-based health interventions and 
support effective and efficient ways of treating drug problems. 
For every level of information (e.g. clinical, regional, national, international, etc.), national and 
international rules of confidentiality and data protection must be considered, as well as rights 
of clients, staff and treatment centres. This is particularly the case for specific treatment settings, 
such as treatment in prison, where high attention must be paid to ethical issues (data protection, 
privacy, human rights), when data are collected and reported.
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These guidelines should adhere to the accepted codes that govern data protection, privacy 
and research in the various countries. Access to the raw data must be restricted to authorised 
professionals only. Use of the data and procedures governing the publishing of results should 
be discussed and agreed by those involved (service providers, managers, policymakers, 
researchers etc.). 
The EMCDDA (with TDI protocol 3.0, as it was the case with TDI protocol 2.0) does not wish 
to develop a central database of individuals entering or being in drug treatment at European 
level. All data are collected, collated, and retained by the countries, with strict adherence to 
accepted ethical standards, and only aggregate data are pooled and analysed for comparative 
purposes on a European level. Individual data sets, however, might occasionally be needed by 
the EMCDDA, as in other fields of research, for specific studies, but only upon agreement with 
the countries.
Annexes
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Table 1: Case definition — graphical description
Client
Treatment 
episode/
activity
Treatment 
centre
Preceding 
year
Current year
Following 
year
Specifications
To be 
reported 
to the 
EMCDDA
A A1 1
Client A is in continuous treatment, 
starting in the previous year, 
continuing throughout the current 
year and into the following year. 
There are no additional treatments. 
No treatment is reported for the 
current year.
B B1 1
Client B is in continuous treatment, 
starting in the previous year, 
continuing throughout the current 
year and into the following year. 
A second treatment occurs during 
the current year in the same 
treatment centre. No treatment is 
reported for the current year. 
(Note: often B2 will be a treatment 
activity — e.g. short-term counselling 
— complementary to the treatment 
B1 — e.g. long-term OST — carried out 
in a planned way for the same drug 
problem that originated the treatment 
entry.)
B B2 1
C C1 1
Client C is in continuous treatment, 
starting in the previous year, 
continuing throughout the current 
year and into the following year. 
Three further treatments occur 
during the current year, in the 
same and two different treatment 
centres. No treatment is reported 
for the current year.
C C2 1
C C3 2
C C4 3
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Table 1 (continued)
Client
Treatment 
episode/
activity
Treatment 
centre
Preceding 
year
Current year
Following 
year
Specifications
To be 
reported 
to the 
EMCDDA
D D1 1
Client D is in treatment from the 
previous year, has no treatments 
starting during the current year, 
has a treatment starting in the 
following year, in the same or 
in a different treatment centre. 
No treatment is recorded for the 
current year.
D D2 Any
E E1 1
Client E enters treatment for the 
first time ever during the current 
year. The treatment is reported 
for the current year as a first-ever 
treatment.
X
F F1 1
Client F starts treatment for the first 
time ever during the current year. 
The treatment continues into the 
following year. The treatment is 
recorded in the current year as a 
first-ever treatment.
X
G G1 2
Client G enters treatment for the 
first time ever during the current 
year, has subsequent treatments 
during the current year, within 
the same and different treatment 
centres. Only G1, the first 
treatment in the current year, is 
reported as a first-ever treatment.
X
G G2 2
G G3 3
H H1 1
Client H has a treatment in the 
previous year that is terminated 
with an end of treatment. A new 
treatment commences during 
the current year, in the same or 
a different treatment centre, and 
extends to the following year. The 
treatment in the current year is 
reported as previously treated.
H H2 Any X
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Table 1 (continued)
Client
Treatment 
episode/
activity
Treatment 
centre
Preceding 
year
Current year
Following 
year
Specifications
To be 
reported 
to the 
EMCDDA
I I1 2
Client I has a treatment in the 
previous year that is terminated 
with an end of treatment. A new 
treatment commences in the 
current year in the same treatment 
centre. A second treatment 
commences in the current year 
in a different treatment centre. 
Treatment I2 is reported on the 
basis that it is the first treatment 
during the year. Treatment I2 is 
reported as previously treated.
I I2 2 X
I I3 3
J J1 1
Client J entered treatment in the 
previous year and that treatment 
continued into the current year. 
Subsequently, a further treatment 
was entered during the current 
year in the same treatment centre. 
Provided a formal end of treatment 
concluded the first treatment, 
the treatment entered during 
the current year is reported as 
previously treated.  
J J2 1 X
K K1 1
Client K entered treatment in the 
previous year and that treatment 
continued into the current year. 
Subsequently, a further treatment 
was entered during the current 
year in the same treatment centre. 
Provided 6 months without contact 
passed between the first and the 
second treatment, the treatment 
entered during the current year is 
reported as previously treated.  
K K2 1 X
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Table 1 (continued)
Client
Treatment 
episode/
activity
Treatment 
centre
Preceding 
year
Current year
Following 
year
Specifications
To be 
reported 
to the 
EMCDDA
L L1 1
Client K entered treatment in the 
previous year and that treatment 
continued into the current year. 
Subsequently, a further treatment 
was entered during the current 
year in a different treatment centre. 
Provided a formal end of treatment 
concluded the first treatment, 
the treatment entered during 
the current year is reported as 
previously treated.   
L L2 2 X
M M1 1
Client K entered treatment in the 
previous year and that treatment 
continued into the current year. 
Subsequently, a further treatment 
was entered during the current 
year in a different treatment centre. 
Provided 6 months without contact 
passed between the first and the 
second treatment, the treatment 
entered during the current year is 
reported as previously treated.   
M M2 2 X
 
Notes: Cases to be included and excluded from data reporting to the EMCDDA and not necessarily from data collection at national or local level.
 To be included: 
 To be excluded:  
  The cases J, K, L and M can be considered variations of the similar situation, for better illustration. They represent clients that were in treatment at the beginning  
 of the year, then the treatment episode was concluded and a new episode (to be notified) started later in the year. The cases represent the combination of two  
 possibilities; when the treatment episode was terminated formally and when it was a drop-out (in that case, the client should have 6 months without contact with  
 a treatment centre, and when the subsequent episode took place in the same centre and when it took place in another centre).
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Table 2: Summary table of comparison: items from TDI version 2.0 and TDI version 3.0
Old items New items
Treatment centre type Data reporting not anymore focusing on treatment centre type
Date of treatment month Dropped at EMCDDA level
Date of treatment year Same
Ever previously treated For more than one episode, the first treatment episode should be recorded
Source of referral Minor modifications in categories and order
Gender Same (word changed)
Age Same (word changed)
Year of birth Dropped at EMCDDA level
Living status (with whom) Clarification of categories to avoid overlap
Living status (where) Clarification and minor change in one category
Nationality Dropped at EMCDDA level
Labour status Harmonisation with Eurostat classification
Highest educational level completed Same; more detailed reference to the ISCED classification
Primary drug Same, with addition of a few substances relevant for drug users in the current situation
Already receiving substitution treatment Similar, but simplified 
Usual route of administration Same
Frequency of use (primary drug) Clarification of some categories
Age at first use of primary drug Same
Ever/currently (last 30 days) in jected Specifications of some categories
Other (=secondary) drugs currently used Same, with addition of a few substances relevant for drug users in the current situation
- - Living status: having children
- - Age at first injection
- - Polydrug use 
- - Age at first OST
- - HIV testing 
- - HCV testing 
- - Needle/syringe sharing
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Abbreviations 
ASI Addiction Severity Index
CICAD Inter-American Drug Abuse Control Commission
DRD Drug-related deaths
DRID Drug-related infectious diseases
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, fourth edition
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
GBL Gamma-Butyrolactone
GHB Gamma-Hydroxybutyric acid
HCl Hydrochloride
HCV Hepatitis C virus
HIV Human Immunodeficiency Virus
ICD-10 International Classification of Diseases, 10th revision
IDU Injection drug user
ISCED International Standard Classification of Education
MDMA Methylenedioxymethamphetamine
NFP  national focal point, institutions and national departments which form the Reitox network
OST Opioid substitution treatment
PDU Problem drug user
PG Council of Europe’s Pompidou Group
Reitox  Réseau Européen d’Information sur les drogues et les Toxicomanies (European 
Information Network on Drugs and Drug Addiction)
SAMHSA Substance Abuse and Mental Health Service Administration
TDI Treatment demand indicator
UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
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one of the European Union’s decentralised agencies. Established in 1993 and 
based in Lisbon, it is the central source of comprehensive information on drugs 
and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, reliable 
and comparable information on drugs and drug addiction. In doing so, it pro-
vides its audiences with an evidence-based picture of the drug phenomenon 
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Guidelines for reporting data on people entering drug treatment
in European countries
